Northwest Biotherapeutics (NWBO) Change in Account Payables (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Change in Account Payables of -$364000.0 for Q1 2026, down 118.02% year-over-year from $2.0 million in Q1 2025, and down 166.06% quarter-over-quarter from $551000.0 in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Change in Account Payables (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$364000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 118.02% year-over-year to -$364000.0; the TTM figure through Mar 2026 stood at $3.6 million (down 4.87% YoY), while the FY2025 annual figure was $5.9 million, up 554.19% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$364000.0, down from $551000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $2.8 million in Q2 2022, with the low at -$2.2 million in Q4 2023.
- The 5-year median for Change in Account Payables is $71000.0 (2022), against an average of $315411.8.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables tumbled 2684.51% in 2023, then surged 715.14% in 2025.
- Northwest Biotherapeutics' Change in Account Payables stood at $1.2 million in 2022, then tumbled by 282.31% to -$2.2 million in 2023, then soared by 162.99% to $1.4 million in 2024, then slumped by 60.89% to $551000.0 in 2025, then sank by 166.06% to -$364000.0 in 2026.
- Business Quant data shows NWBO's Change in Account Payables at -$364000.0 in Q1 2026, $551000.0 in Q4 2025, and $1.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -364,000.00 |
| Dec 31, 2025 | 551,000.00 |
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | 1.41 Mn |
| Sep 30, 2024 | 560,000.00 |
| Jun 30, 2024 | -251,000.00 |
| Mar 31, 2024 | -810,000.00 |
| Dec 31, 2023 | -2.24 Mn |
| Sep 30, 2023 | -1.84 Mn |
| Jun 30, 2023 | -63,000.00 |
| Mar 31, 2023 | -341,000.00 |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 2.75 Mn |
| Mar 31, 2022 | -694,000.00 |
| Dec 31, 2021 | 1.17 Mn |
| Sep 30, 2021 | 800,000.00 |
| Jun 30, 2021 | 483,000.00 |